{"nctId":"NCT01323478","briefTitle":"Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults","startDateStruct":{"date":"2011-04"},"conditions":["Major Depressive Disorder"],"count":71,"armGroups":[{"label":"Vortioxetine","type":"EXPERIMENTAL","interventionNames":["Drug: Vortioxetine (Lu AA21004)"]}],"interventions":[{"name":"Vortioxetine (Lu AA21004)","otherNames":["Brintellix"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPatients who completed 8-week short-term treatment study, 13267A (NCT01140906), for Major Depressive Episode immediately prior to enrolment in this extension study\n\nExclusion Criteria:\n\n* Any current psychiatric disorder other than MDD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV TR)\n* Female patients of childbearing potential who are not using effective contraception\n* Use of any psychoactive medication\n* The patient, in the investigator's clinical judgment, has a significant risk of suicide.\n\nOther protocol-defined inclusion and exclusion criteria applied.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Adverse Events (AEs)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients Who Withdrew Due to Intolerance to Treatment","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in MADRS Total Score After 52 Weeks of Treatment","description":"The Montgomery Ã…sberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.9","spread":"9.99"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-S Score After 52 Weeks of Treatment","description":"The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.49","spread":"1.46"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment","description":"The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.85","spread":"7.49"}]}]}]},{"type":"SECONDARY","title":"Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.9","spread":null}]}]}]},{"type":"SECONDARY","title":"SDS Total Score After 52 Weeks of Treatment","description":"The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.85","spread":"5.84"}]}]}]},{"type":"SECONDARY","title":"ASEX Total Score After 52 Weeks of Treatment","description":"The Arizona Sexual Experience Scale (ASEX) is a 5-item, patient selfrated scale that evaluates a patient's recent sexual experience. Patients are asked to assess their own experience over the last week (for example, \"How strong is your sex drive?\", \"Are your orgasms satisfying?\") and respond on a 6-point scale for each item. The ASEX is used to identify individuals with sexual dysfunction. Possible total score ranges from 5 to 30, with the higher score indicating more patient sexual dysfunction.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.60","spread":"0.96"}]}]}]},{"type":"SECONDARY","title":"Risk of Suicidality Using C-SSRS Scores","description":"The Columbia-Suicide Severity Rating Scale (C-SSRS) was developed by researchers at Columbia University as a tool to systematically assess suicidal ideation and behaviour in patients during participation in a clinical study. The C-SSRS is composed of questions that address suicidal behaviour and questions that address suicidal ideation, with subquestions that assess severity. The tool was administered via an interview with the patient. Different versions of the C-SSRS are available. In this study, the Since Last Visit Version was used at all visits. In order to assess the potential relationship between Vortioxetine and suicidality more accurately and systematically, C-SSRS data were collected during the Entire Study Period.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":71},"commonTop":["Nausea","Dizziness","Headache","Nasopharyngitis","Insomnia"]}}}